keyword
https://read.qxmd.com/read/38376657/pharmacokinetics-of-dasatinib-in-rats-a-potential-food-drug-interaction-with-naringenin
#21
JOURNAL ARTICLE
Mohammad Raish, Ajaz Ahmad, Badr Abdul Karim, Yousef A Bin Jardan, Abdul Ahad, Muzaffar Iqbal, Khalid M Alkharfy, Fahad I Al-Jenoobi, Omer Mansour Mohammed
BACKGROUND AND OBJECTIVES: The novel tyrosine kinase inhibitor (TKI) dasatinib, a multitarget inhibitor of Bcr-Abl and Src family kinases, has been licensed for the treatment of Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia. Many citrus-based foods include the flavonoid naringenin, which is commonly available. Dasatinib is a Cyp3a4, P-gp, and Bcrp1 substrate, which makes it sensitive to potential food-drug interactions. The concurrent use of naringenin may change the pharmacokinetics of dasatinib, which could result in adverse effects and toxicity...
February 20, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38375783/the-mozart-effect-in-chronic-myeloid-leukaemia
#22
JOURNAL ARTICLE
Jesper Stentoft
Clinical research has not been able to establish whether the differences between first- and second-generation BCR-ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by Alcazer et al., a relevant difference seems to emerge-paradoxically in the absence of the drugs-as demonstrated by differences in the relapse kinetics after cessation of therapy. Commentary on: Alcazer et al. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients...
February 20, 2024: British Journal of Haematology
https://read.qxmd.com/read/38368446/inhibition-of-lats-kinases-reduces-tumorigenicity-and-increases-the-sensitivity-of-human-chronic-myelogenous-leukemia-cells-to-imatinib
#23
JOURNAL ARTICLE
Phatchanat Klaihmon, Chanchao Lorthongpanich, Pakpoom Kheolamai, Wannachai Saisaard, Surapol Issaragrisil
Chronic myelogenous leukemia (CML) is a clonal hematologic malignancy of the myeloid lineage caused by the oncogenic BCR/ABL fusion protein that promotes CML cell proliferation and protects them against drug-induced apoptosis. In this study, we determine LATS1 and LATS2 expression in CML cells derived from patients who are resistant to imatinib (IM) treatment. Significant upregulation of LATS1 and LATS2 was found in these CML patients compared to healthy donors. To further explore whether the expression of LATS1/2 contributes to the IM-resistant phenotype, IM-resistant CML cell lines generated by culturing CML-derived erythroblastic K562 cells in increasing concentrations of IM were used as in vitro models...
February 18, 2024: Scientific Reports
https://read.qxmd.com/read/38363412/occurrence-of-existing-bcr-abl-baseline-mutations-and-associated-haplotype-nmr-among-cml-patients-with-diverse-im-response-a-hospital-based-study-from-north-east-india
#24
JOURNAL ARTICLE
Gautam Hazarika, Manash Jyoti Kalita, Partha Pratim Das, Simanta Kalita, Kalpajit Dutta, Lipika Lahkar, Anjanjyoti Rajkonwar, Mohammed Ghaznavi Idris, Vinotsale Khamo, Giriraj Kusre, Subhash Medhi
Highly polymorphic BCR-ABL kinase domains have been reported to harbor more than a hundred mutations, and among these, 40-60% have been identified as influencers of imatinib mesylate (IM) resistance. The emergence of IM resistance poses a significant challenge in the management of Chronic Myeloid Leukemia (CML). M351T (rs121913457), E255K (rs387906517), and Y253H (rs121913461) are of particular clinical significance due to their association with high-level imatinib resistance. This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance...
February 16, 2024: Biochemical Genetics
https://read.qxmd.com/read/38360178/lipopolymer-mediated-sirna-delivery-targeting-aberrant-oncogenes-for-effective-therapy-of-myeloid-leukemia-in-preclinical-animal-models
#25
JOURNAL ARTICLE
Aysha S Ansari, Remant K C, Luis C Morales, Mohammed Nasrullah, Daniel Nisakar Meenakshi Sundaram, Cezary Kucharski, Xiaoyan Jiang, Joseph Brandwein, Hasan Uludağ
The clinical development of tyrosine kinase inhibitors (TKI) has led to great strides in improving the survival of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) patients. But even the new generation TKIs are rendered futile in the face of evolving landscape of acquired mutations leading to drug resistance, necessitating the pursuit of alternative therapeutic approaches. In contrast to exploiting proteins as targets like most conventional drugs and TKIs, RNA Interference (RNAi) exerts its therapeutic action towards disease-driving aberrant genes...
February 15, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38345995/prognostic-factors-in-philadelphia-chromosome-positive-acute-myeloid-leukemia-using-fluorescence-in-situ-hybridization
#26
JOURNAL ARTICLE
Zhaohua Zhang, Chuan Sun, Lingyi Cai, Ying Chen, Xinyi Zhou, Suipeng Chen, Xiao Feng, Xiangchou Yang, Qian Li, Lihua Liu, Haixia Zhou, Baoqing Li
BACKGROUND: Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) is a rare leukemia subtype first classified by the World Health Organization in 2016. The incidence of Ph+ AML is approximately 0.5 - 3%, and its prognosis is poor. Ph+ AML with additional chromosomal abnormalities in children has rarely been reported, and its treatment and prognosis remain uncertain. METHODS: We retrospectively analyzed 649 patients with AML from 2006 - 2021. Six (0.9%) patients with Ph+ AML were identified and treated with conventional chemotherapy...
February 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38340217/bcr-abl-positive-chronic-myeloid-leukemia-in-children-current-treatment-approach
#27
REVIEW
Jenna M Menger, Ryan S Sathianathen, Kathleen M Sakamoto, Nobuko Hijiya
PURPOSE OF REVIEW: The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation. RECENT FINDINGS: There is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission in children. Chronic phase CML in children is managed with lifelong TKI therapy; however, evidence of deeper remissions sustained with second-generation TKIs may permit shorter treatment courses...
February 10, 2024: Current Oncology Reports
https://read.qxmd.com/read/38337818/novel-four-way-variant-translocation-t-1-9-22-16-q21-q34-q11-2-q24-in-a-patient-with-chronic-myeloid-leukemia
#28
JOURNAL ARTICLE
Han Joon Son, Jong Ho Lee
Chronic myeloid leukemia (CML) is characterized by the Philadelphia (Ph) chromosome resulting from the translocation of t(9;22)(q34;q11), producing the BCR :: ABL1 fusion gene. Variant Ph chromosome translocations, involving rearrangements in chromosomes other than 9 and 22, occur in 5-10% of CML cases. Herein, we report a unique case of a 36-year-old male with a four-way variant Ph chromosome. Conventional chromosomal analysis performed on bone marrow aspirate samples showed 46, XY, t(1;9;22;16)(q21;q34;q11...
January 30, 2024: Diagnostics
https://read.qxmd.com/read/38325182/zinc-as-a-potential-regulator-of-the-bcr-abl-oncogene-in-chronic-myelocytic-leukemia-cells
#29
JOURNAL ARTICLE
Bo Zhu, Longshuo Sun, Zhonghua Li, Pengyou Shang, Chunhao Yang, Kaiqiang Li, Jiahuang Li, Qi Zhi, Zichun Hua
BACKGROUND: Generally, decreased zinc in the serum of tumor patients but increased zinc in tumor cells can be observed. However, the role of zinc homeostasis in myeloid leukemia remains elusive. BCR-ABL is essential for the initiation, maintenance, and progression of chronic myelocytic leukemia (CML). We are currently investigating the association between zinc homeostasis and CML. METHODS: Genes involved in zinc homeostasis were examined using three GEO datasets...
February 2, 2024: Journal of Trace Elements in Medicine and Biology
https://read.qxmd.com/read/38312177/the-outcome-of-pediatric-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-experience-from-a-referral-center-in-south-india
#30
JOURNAL ARTICLE
Nikita Antonisamy, Deepthi Boddu, Rikki John, Richa Sharon Angel Korrapolu, Poonkuzhali Balasubramanian, Arun Kumar Arunachalam, Leenu Lizbeth Joseph, Hema Nalapullu Srinivasan, Leni Grace Mathew, Sidharth Totadri
UNLABELLED: Although improved survival in children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) has been demonstrated in trials, the outcome appears to be inferior in low- and middle-income countries (LMIC). Methods A file review of children aged ≤ 15 years diagnosed with Ph-ALL from 2010 to 2019 was performed. Minimal residual disease (MRD) was assessed by flow-cytometry. Real-time polymerase chain reaction (qRT-PCR) was used to quantify the BCR::ABL1 transcripts during treatment...
January 2024: Indian Journal of Hematology & Blood Transfusion
https://read.qxmd.com/read/38307941/state-transition-modeling-of-blood-transcriptome-predicts-disease-evolution-and-treatment-response-in-chronic-myeloid-leukemia
#31
JOURNAL ARTICLE
David E Frankhouser, Russell C Rockne, Lisa Uechi, Dandan Zhao, Sergio Branciamore, Denis O'Meally, Jihyun Irizarry, Lucy Ghoda, Haris Ali, Jeffery M Trent, Stephen Forman, Yu-Hsuan Fu, Ya-Huei Kuo, Bin Zhang, Guido Marcucci
Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). TKIs can induce long-term remission but are also not curative. Thus, CML is an ideal system to test our hypothesis that transcriptome-based state-transition models accurately predict cancer evolution and treatment response. We collected time-sequential blood samples from tetracycline-off (Tet-Off) BCR::ABL-inducible transgenic mice and wild-type controls. From the transcriptome, we constructed a CML state-space and a three-well leukemogenic potential landscape...
February 2, 2024: Leukemia
https://read.qxmd.com/read/38294463/-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia
#32
JOURNAL ARTICLE
Delphine Réa
TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA. About 20 years ago, the discovery of imatinib, the first ATP-competitive inhibitor of BCR::ABL1 the driving oncoprotein of chronic myeloid leukemia (CML), revolutionized patients' outcome by transforming a fatal condition into a chronic one. Today, five more tyrosin kinase inhobitors (TKIs) have been approved, allowing to some extent individualization of drug therapy. The main therapeutic objective is to protect patients from progression towards a fatal blast crisis and to restore of a near-to-normal life expectancy on lifelong TKI treatment...
December 2023: La Revue du Praticien
https://read.qxmd.com/read/38291705/biodistribution-of-therapeutic-small-interfering-rnas-delivered-with-lipid-substituted-polyethylenimine-based-delivery-systems
#33
JOURNAL ARTICLE
Luis C Morales, Amarnath Rajendran, Aysha Ansari, Remant Kc, Mohammad Nasrullah, Kitipong Kiti, Panadda Yotsomnuk, Marianna Kulka, Daniel Nisakar Meenakshi Sundaram, Hasan Uludağ
Small interfering RNAs (siRNAs) have emerged as a powerful tool to manipulate gene expression in vitro . However, their potential therapeutic application encounters significant challenges, such as degradation in vivo, limited cellular uptake, and restricted biodistribution, among others. This study evaluates the siRNA delivery efficiency of three different lipid-substituted polyethylenimine (PEI)-based carriers, named Leu-Fect A-C, to different organs in vivo , including xenograft tumors, when injected into the bloodstream of mice...
January 30, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38280275/the-impact-of-the-bcr-abl-oncogene-in-the-pathology-and-treatment-of-chronic-myeloid-leukemia
#34
REVIEW
Mohamed El-Tanani, Hamdi Nsairat, Ismail I Matalka, Yin Fai Lee, Manfredi Rizzo, Alaa A Aljabali, Vijay Mishra, Yachana Mishra, Altijana Hromić-Jahjefendić, Murtaza M Tambuwala
Chronic Myeloid Leukemia (CML) is characterized by chromosomal aberrations involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a reciprocal translocation between chromosomes 9 and 22. This fusion gives rise to the oncogenic BCR-ABL, an aberrant tyrosine kinase identified as Abl protein. The Abl protein intricately regulates the cell cycle by phosphorylating protein tyrosine residues through diverse signaling pathways. In CML, the BCR-ABL fusion protein disrupts the first exon of Abl, leading to sustained activation of tyrosine kinase and resistance to deactivation mechanisms...
January 22, 2024: Pathology, Research and Practice
https://read.qxmd.com/read/38261414/three-way-philadelphia-translocation-t-46-xx-t-9-22-16-q34-q11-2-q24-in-chronic-myeloid-leukemia-a-report-of-two-cases-with-review-of-the-literature
#35
JOURNAL ARTICLE
Mohit Bhardwaj, Sourav K Mishra, Aastha Gupta, Prashant Mehta, Shivani Sharma, Sambit K Mohanty
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm that is genetically characterized by the presence of the Philadelphia (Ph) chromosome. Variant Ph translocation has been observed in 5% to 10% of the CML cases. In the previous studies, many different types of variant Ph translocations have been observed involving chromosomes 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, and 10p15. According to the published literature, only two cases with the complex translocations involving long arm of chromosome 16 at band q24 have been reported...
January 22, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38241589/chronic-myeloid-leukemia-with-two-rare-fusion-gene-transcripts-of-atypical-bcr-abl-a-case-report-and-literature-review
#36
JOURNAL ARTICLE
Yuxin Li, Yilin Zhang, Xin Meng, Sheping Chen, Ting Wang, Longjin Zhang, Xiaorong Ma
RATIONALE: Imatinib is a standard treatment for Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML), but its efficacy in rare BCR::ABL variants is underexplored. PATIENT CONCERNS: A 67-year-old woman was admitted to the Second Affiliated Hospital of Xi'an Jiaotong University in March 2022 due to elevated white blood cells. DIAGNOSIS: Karyotype analysis revealed clonal abnormalities involving the variant t(9;22) and positive results for atypical BCR::ABL variants (e14a3 and e13a3)...
January 19, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38234720/identification-of-a-musashi2-translocation-as-a-novel-oncogene-in-myeloid-leukemia
#37
Kyle Spinler, Michael Hamilton, Jeevisha Bajaj, Yutaka Shima, Emily Diaz, Marcie Kritzik, Tannishtha Reya
Myeloid leukemias, diseases marked by aggressiveness and poor outcomes, are frequently triggered by oncogenic translocations. In the case of chronic myelogenous leukemia (CML) the BCR-ABL fusion initiates chronic phase disease with second hits allowing progression to blast crisis. Although Gleevec has been transformative for CML, blast crisis CML remains relatively drug resistant. Here we show that MSI2-HOXA9, a translocation with an unknown role in cancer, can serve as a second hit in driving bcCML. Compared to BCR-ABL, BCR-ABL/MSI2-HOXA9 led to a more aggressive disease in vivo with decreased latency, increased lethality and a differentiation blockade that is a hallmark of blast crisis...
December 29, 2023: bioRxiv
https://read.qxmd.com/read/38216843/role-of-mirnas-to-control-the-progression-of-chronic-myeloid-leukemia-by-their-expression-levels
#38
REVIEW
Manvi Bansal, Sana Ansari, Malkhey Verma
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder distinguished by a specific genetic anomaly known as a reciprocal translocation between chromosomes 9 and 22. This translocation causes fusion between the BCR and ABL regions. Consequently, BCR::ABL oncoprotein is formed, which plays a significant role in driving CML progression. Imatinib, a tyrosine kinase inhibitor (TKI), became the first line of drugs against CML. However, with continuous treatment, patients developed resistance against it. Indeed, to address this challenge, microRNA-based therapy emerges as a promising approach...
January 12, 2024: Medical Oncology
https://read.qxmd.com/read/38215931/cell-penetrating-peptide-and-cationic-liposomes-mediated-sirna-delivery-to-arrest-growth-of-chronic-myeloid-leukemia-cells-in%C3%A2-vitro
#39
JOURNAL ARTICLE
Vera Vysochinskaya, Yana Zabrodskaya, Olesya Dovbysh, Anton Emelyanov, Vladimir Klimenko, Nikolay Knyazev, Ivan Terterov, Marya Egorova, Alexey Bogdanov, Michael Maslov, Andrey Vasin, Michael Dubina
Gene silencing through RNA interference (RNAi) is a promising therapeutic approach for a wide range of disorders, including cancer. Non-viral gene therapy, using specific siRNAs against BCR-ABL1, can be a supportive or alternative measure to traditional chronic myeloid leukemia (CML) tyrosine kinase inhibitor (TKIs) therapies, given the prevalence of clinical TKI resistance. The main challenge for such approaches remains the development of the effective delivery system for siRNA tailored to the specific disease model...
January 10, 2024: Biochimie
https://read.qxmd.com/read/38204488/donor-derived-anti-cd19-car-t-cells-gc007g-for-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-after-allogeneic-hsct-a-phase-1-trial
#40
JOURNAL ARTICLE
Yi Luo, Lei Gao, Jia Liu, Luxin Yang, Lu Wang, Xiaoyu Lai, Shichun Gao, Lizhen Liu, Lu Zhao, Yishan Ye, Manning Wang, Lianjun Shen, W William Cao, Dongrui Wang, Wenling Li, Xi Zhang, He Huang
BACKGROUND: Although chimeric antigen receptor-modified T cells (CAR T) cell therapy has been widely reported in improving the outcomes of B-cell acute lymphoblastic leukemia (B-ALL), less research about the feasibility and safety of donor-derived CAR T after allogeneic hematopoietic stem cell transplantation (allo-HSCT) was reported. METHODS: This phase 1 clinical trial aims to evaluate safety and efficacy of donor-derived anti-CD19 CAR T cells (GC007g) in B-ALL patients who relapsed after allo-HSCT...
January 2024: EClinicalMedicine
keyword
keyword
24732
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.